Another strategy to counteract the immunosuppressive TME and to improve persistence and anti-tumor ability of CAR T cells, is to engineer CAR T cells to autonomously express immune-stimulating cytokines, such as IL-15 (118), IL-12 (119), IL-18 (120–123) and IL-23 (124). The gene discussed is IL15; the disease is neoplasm.